Onivyde pegylated liposomal (previously known as Onivyde) Euroopa Liit - islandi - EMA (European Medicines Agency)

onivyde pegylated liposomal (previously known as onivyde)

les laboratoires servier - irinotecan anhydrous free-base - brisbólga - Æxlishemjandi lyf - meðferð af sjúklingum krabbamein í brisi í bland með 5 fluorouracil (5 fu) og leukovorin (vuitton), í fullorðinn sjúklingar sem hafa gengið eftir gemcitabin byggt meðferð.

Dexmedetomidine Accord Euroopa Liit - islandi - EMA (European Medicines Agency)

dexmedetomidine accord

accord healthcare s.l.u. - dexmedetomidine - lyfjaforgjöf - psycholeptics - fyrir róandi fullorðinna gjÖrgÆslu (gjörgæsludeild) sjúklingar sem krefjast róandi stigi ekki dýpra en örvun til að bregðast við munnleg örvun (svarar til richmond Æsingur-róandi mælikvarða (rass) 0 að -3). fyrir róandi ekki með leiðslur fullorðinn sjúklinga áður og/eða á greiningu eða skurðaðgerðir þurfa róandi, ég. málsmeðferð/vakandi róandi.

Zeposia Euroopa Liit - islandi - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod stutt og long-term - multiple sclerosis, relapsing-remitting; colitis, ulcerative - Ónæmisbælandi lyf - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Sogroya Euroopa Liit - islandi - EMA (European Medicines Agency)

sogroya

novo nordisk a/s - somapacitan - vöxtur - hinsveiflur og heilahimnubólur og hliðstæður - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Sugammadex Mylan Euroopa Liit - islandi - EMA (European Medicines Agency)

sugammadex mylan

mylan ireland limited - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Fresenius Kabi Euroopa Liit - islandi - EMA (European Medicines Agency)

sugammadex fresenius kabi

fresenius kabi deutschland gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Sugammadex Amomed Euroopa Liit - islandi - EMA (European Medicines Agency)

sugammadex amomed

aop orphan pharmaceuticals gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - afturköllun taugavöðvablokkunar sem valdið er af rócuronium eða vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Apomorfin PharmSwed Innrennslislyf, lausn 5 mg/ml Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

apomorfin pharmswed innrennslislyf, lausn 5 mg/ml

evolan pharma ab - apomorphin hýdróklóríð - innrennslislyf, lausn - 5 mg/ml

Diltiazem HCl Alvogen (Dilmin) Forðatafla 120 mg Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

diltiazem hcl alvogen (dilmin) forðatafla 120 mg

alvogen ehf. - diltiazemum hýdróklóríð - forðatafla - 120 mg

Trilafon Dekanoat (Trilafon dekanoat) Stungulyf, lausn 108 mg/ml Island - islandi - LYFJASTOFNUN (Icelandic Medicines Agency)

trilafon dekanoat (trilafon dekanoat) stungulyf, lausn 108 mg/ml

orion corporation - perphenazinum dekanóat - stungulyf, lausn - 108 mg/ml